Mechanisms of drug inhibition of signalling molecules

Judith S. Sebolt-Leopold () and Jessie M. English
Additional contact information
Judith S. Sebolt-Leopold: Pfizer Global Research and Development, Michigan Laboratories
Jessie M. English: Pfizer Research Technology Center

Nature, 2006, vol. 441, issue 7092, 457-462

Abstract: Abstract The emergence of tumour-specific, molecularly targeted agents signifies a paradigm shift in cancer therapy, with less reliance on drugs that non-discriminately kill tumour and host cells. Although the diversity of targets giving rise to this new generation of anticancer drugs has expanded, many challenges persist in the design of effective treatment regimens. The complex interplay of signal-transduction pathways further complicates the customization of cancer treatments to target single mechanisms. However, despite uncertainty over precise or dominant mechanisms of action, especially for compounds targeting multiple gene products, emerging agents are producing significant therapeutic advances against a broad range of human cancers.

Date: 2006
References: Add references at CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/nature04874 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:441:y:2006:i:7092:d:10.1038_nature04874

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/nature04874

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().